Curium to Merge with Lantheus in $8B Radiopharma Deal
Boston & Bedford, Massachusetts, August 3, 2026 Curium and Lantheus Holdings, Inc. have entered into a definitive merger agreement...
radioligand therapy
Advertisement
Novartis’ Pluvicto Wins FDA Approval for Earlier Prostate Cancer Treatment
SILVER SPRING, Md., July 31, 2026 The U.S. Food and Drug Administration (FDA) has approved Novartis’ Pluvicto (lutetium Lu...
Ratio Therapeutics Raises $70 Million to Advance Radiotherapeutics
BOSTON, July 31, 2026 Ratio Therapeutics announced the successful closing of a $70 million Series C financing, increasing the...
Immunome Doses First Patient in Phase 1 IM-3050 Radioligand Therapy Trial
BOTHELL, Wash., July 20, 2026 Immunome, Inc. (Nasdaq: IMNM) announced that the first patient has been dosed in the...
C Ray Therapeutics Secures Key Radiopharmaceutical License
CHENGDU, China, June 2026 C Ray Therapeutics (Chengdu) Co., Ltd. announced that it has officially obtained a Radiopharmaceutical Manufacturing...
Advertisements
Teva Highlights Long-Term AUSTEDO Success in Tardive Dyskinesia Care
PARSIPPANY, N.J. and TEL AVIV, Israel, June 20, 2026 Teva Pharmaceutical Industries Ltd. has unveiled compelling new long-term data...
Curium Court Victory Clears Path for U.S. GEP-NET Therapy
BOSTON, MA, June 18, 2026 Curium™ has secured a significant legal and commercial milestone after prevailing in a patent...
Curium Invests €32M to Expand Prostate Cancer RLT Production
PARIS, France, June 1, 2026 Curium, a global leader in radiopharmaceuticals and nuclear medicine, has announced a strategic investment...
Novartis Highlights New Cancer Data at ASCO & EHA 2026
BASEL, Switzerland, May 21, 2026 Novartis announced it will present more than 65 company-sponsored and investigator-sponsored abstracts at the...
Telix Advances TLX597-Tx Phase 2 Prostate Cancer Program
MELBOURNE, Australia & INDIANAPOLIS, IN, April 30, 2026 Telix Pharmaceuticals has announced encouraging dosimetry results from its Phase 2...
Advertisement
